Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,395 INR | -0.98% | +3.21% | +12.20% |
04:07am | Cipla Arm Completes Acquisition of Ivia's Cosmetics, Personal-Care Marketing Business | MT |
24/04 | Indian Equities End Higher Midweek as Iran-Israel Conflict Subsides | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.57 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 4.19 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.20% | 13.64B | B+ | ||
+20.68% | 43.34B | B- | ||
+20.44% | 21.96B | B+ | ||
+10.86% | 14.09B | - | ||
+39.52% | 11.43B | B | ||
-8.59% | 6.86B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+8.46% | 5.22B | B+ | ||
-4.29% | 4.71B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CIPLA Stock
- Ratings Cipla Limited